Bellerophon Therapeutics (BLPH) Stock Price, News & Analysis

Company Overview

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Key Stats

• Today's Range: $0.04 to $0.04
• 50-Day Range: $0.04 to $0.04
• 52-Week Range: $0.03 to $0.10
• Volume: 2,872 shs
• Average Volume: 2,733 shs
• Market Capitalization: $464,740.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Bellerophon Therapeutics Stock Analysis - MarketRank™

Bellerophon Therapeutics scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Bellerophon Therapeutics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Bellerophon Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bellerophon Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bellerophon Therapeutics has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BLPH.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bellerophon Therapeutics does not currently pay a dividend.

Dividend Growth

Bellerophon Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.86

Short Interest

There is no current short interest data available for BLPH.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Bellerophon Therapeutics this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for BLPH on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bellerophon Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.20% of the stock of Bellerophon Therapeutics is held by insiders.

Percentage Held by Institutions

Only 10.61% of the stock of Bellerophon Therapeutics is held by institutions.

BLPH Stock Analysis - Frequently Asked Questions

How have BLPH shares performed this year?

Bellerophon Therapeutics' stock was trading at $0.0370 at the start of the year. Since then, BLPH stock has increased by 2.7% and is now trading at $0.0380.
View the best growth stocks for 2024 here.

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) released its quarterly earnings data on Monday, August, 14th. The biotechnology company reported ($0.42) earnings per share for the quarter.

When did Bellerophon Therapeutics' stock split?

Bellerophon Therapeutics shares reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Bellerophon Therapeutics IPO?

Bellerophon Therapeutics (BLPH) raised $60 million in an initial public offering on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

How do I buy shares of Bellerophon Therapeutics?

Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Bellerophon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bellerophon Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), iBio (IBIO) and Meta Platforms (META).

Company Calendar

• Last Earnings: 8/14/2023
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BLPH
• CUSIP: N/A
• CIK: 1600132
• Web: www.bellerophon.com
• Phone: (908) 574-4770
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.27 per share
• Price / Book: 0.14

Miscellaneous

• Outstanding Shares: 12,230,000
• Free Float: 11,597,000
• Market Cap: $464,740.00
• Optionable: No Data
• Beta: 0.71